Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab and Erlotinib in Refractory Pancreatic Adenocarcinoma
NCT01108458Phase 2Terminated
- Start
- Jul 2010
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in pancreatic adenocarcinoma (PDAC). Started Jul 2010; status: terminated.
02
Drugs
pertuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01108458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01108458.